In late July, the Senate passed the $280 billion CHIPS Act to give the semiconductor industry funding to compete with China and protect U.S. national interests. Then, on the same day, Senate Majority Leader Chuck Schumer and Sen. Joe Manchin announced a deal to revive a budget reconciliation bill with drug price controls that, in stark contrast, would help China compete and take market share from the U.S. biopharma industry.
